Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Eprodisate

Drug Profile

Eprodisate

Alternative Names: Eprodisate disodium; Eprodisate sodium; Fibrillex; Kiacta; NC-503

Latest Information Update: 28 Jun 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BELLUS Health
  • Developer Auven Therapeutics; BELLUS Health
  • Class Alkanes; Anti-inflammatories; Small molecules; Sulfonic acids
  • Mechanism of Action Serum amyloid A protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyloidosis
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Submission Withdrawal Amyloid A amyloidosis
  • No development reported Sarcoidosis
  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 28 Jun 2018 No recent reports of development identified for preclinical development in Sarcoidosis in USA (PO)
  • 24 Jun 2018 Biomarkers information updated
  • 21 Dec 2016 Discontinued - Phase-III for Amyloid A amyloidosis in USA, European Union, Russia, Israel, Peru, Mexico, India, Argentina, Turkey, Brazil, Chile, Egypt, Tunisia, Ukraine, Georgia, Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top